The current P/E ratio for Supernus Pharmaceuticals stock as of Apr 2, 2025 is 24.49. This is calculated based on the TTM EPS of $1.34 and the stock price of $32.82 per share.
The average historical PE ratio of Supernus Pharmaceuticals for the last ten years is 74.58. The current price-to-earnings ratio of 24.49 is 67% less than the historical average. Analyzing the last ten years, SUPN's PE ratio reached its highest point in the Dec 2023 quarter at 1,447, when the price was $28.94 and the EPS was $0.02. The lowest point was recorded in the Mar 2020 quarter, when it reached 8.14 with a price of $17.99 and an EPS of $2.21.
Maximum annual increase: 4,483.47% in 2023
Maximum annual decrease: -98.13% in 2024
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 26.99 | -98.13% | $36.16 | $1.34 |
2023 | 1,447 | 4,483.47% | $28.94 | $0.02 |
2022 | 31.57 | 9.35% | $35.67 | $1.13 |
2021 | 28.87 | 176.53% | $29.16 | $1.01 |
2020 | 10.44 | -4.92% | $25.16 | $2.41 |
2019 | 10.98 | -29.62% | $23.72 | $2.16 |
2018 | 15.6 | -55.77% | $33.22 | $2.13 |
2017 | 35.27 | 157.07% | $39.85 | $1.13 |
2016 | 13.72 | -70.39% | $25.25 | $1.84 |
2015 | 46.34 | N/A | $13.44 | $0.29 |
2014 | N/A | N/A | $8.3 | -$0.26 |
2013 | N/A | N/A | $7.54 | -$2.9 |
2012 | N/A | N/A | $7.17 | -$2.72 |
2011 | N/A | N/A | N/A | $31.39 |
2010 | N/A | N/A | N/A | -$26.38 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 26.99 | -6.51% | $36.16 | $1.34 |
Sep 2024 | 28.87 | -90.29% | $31.18 | $1.08 |
Jun 2024 | 297.22 | N/A | $26.75 | $0.09 |
Mar 2024 | N/A | N/A | $34.11 | -$0.29 |
Dec 2023 | 1,447 | 2,366.76% | $28.94 | $0.02 |
Sep 2023 | 58.66 | 54.17% | $27.57 | $0.47 |
Jun 2023 | 38.05 | 0.82% | $30.06 | $0.79 |
Mar 2023 | 37.74 | 19.54% | $36.23 | $0.96 |
Dec 2022 | 31.57 | -33.79% | $35.67 | $1.13 |
Sep 2022 | 47.68 | 79.72% | $33.85 | $0.71 |
Jun 2022 | 26.53 | 14.11% | $28.92 | $1.09 |
Mar 2022 | 23.25 | -19.47% | $32.32 | $1.39 |
Dec 2021 | 28.87 | 67.75% | $29.16 | $1.01 |
Sep 2021 | 17.21 | 6.17% | $26.67 | $1.55 |
Jun 2021 | 16.21 | 30.62% | $30.79 | $1.9 |
The current PE ratio of SUPN is under its 3, 5 and 10-year averages.
SUPN's PE ratio is less than its peer stocks LLY and JNJ, but it is above ABT's and UTHR's. Supernus Pharmaceuticals is currently trading at a lower PE ratio (24.49) than its peers average of 31.3.
Stock name | PE ratio | Market cap |
---|---|---|
UTHR UNITED THERAPEUTICS Corp | 11.57 | $13.74B |
ABT Abbott Laboratories | 17.26 | $229.62B |
SUPN Supernus Pharmaceuticals Inc | 24.22 | $1.81B |
JNJ Johnson & Johnson | 27.41 | $385.34B |
LLY ELI LILLY & Co | 67.41 | $751.69B |
BMY Bristol Myers Squibb Co | N/A | $118.85B |
The price to earnings ratio for SUPN stock as of Apr 2, 2025, stands at 24.49.
Over the last 3 years, the average PE ratio for SUPN stock is 204.03.
Over the last 5 years, the average PE ratio for SUPN stock is 120.43.
The highest quarterly PE ratio in the last ten years has been 1,447 and it was in the Dec 2023 quarter.
The current PE ratio of SUPN is 67% lower than the 10-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Apr 2, 2025), Supernus Pharmaceuticals's share price is $32.82. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $1.34. Therefore, Supernus Pharmaceuticals's price to earnings ratio for today is 24.49. PE RATIO(24.49) = STOCK PRICE($32.82) / TTM EPS($1.34)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.